| Full Name | Polyglutamine Binding Protein 1 |
|---|---|
| Gene Symbol | PQBP1 |
| Chromosomal Location | Xp11.23 |
| NCBI Gene ID | [5407](https://www.ncbi.nlm.nih.gov/gene/5407) |
| OMIM | [300463](https://www.omim.org/entry/300463) |
| Ensembl ID | ENSG00000102172 |
| UniProt | [Q96A73](https://www.uniprot.org/uniprot/Q96A73) |
| Protein Length | 312 amino acids |
| Associated Diseases | [Renpenning Syndrome](/diseases/renpenning-syndrome), [Huntington's Disease](/diseases/huntingtons-disease), [ALS](/diseases/als), [Spinocerebellar Ataxias](/diseases/ataxias) |
The PQBP1 (Polyglutamine Binding Protein 1) gene encodes a small nuclear protein that specifically binds to polyglutamine (polyQ) tracts found in various disease proteins. Originally identified for its interaction with expanded polyglutamine proteins in Huntington's disease and related disorders, PQBP1 has emerged as a critical regulator of transcription, RNA processing, and more recently, as a causative gene for X-linked intellectual disability syndromes[1][2].
PQBP1 is a highly conserved nuclear protein expressed throughout the brain and peripheral tissues. Its dual roles—as a transcriptional regulator in normal cellular function and as a pathological interactor with expanded polyglutamine proteins—make it a unique nexus between developmental disorders and adult-onset neurodegeneration. The discovery of PQBP1 mutations as causes of Renpenning syndrome and related X-linked disorders highlighted its essential role in neural development, while studies in various disease models have revealed its involvement in the pathogenic mechanisms of polyglutamine diseases, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[3][4].
PQBP1 was initially characterized as a protein that binds specifically to expanded polyglutamine tracts, which are the pathological hallmark of Huntington's disease and several spinocerebellar ataxias. The protein contains multiple functional domains, including an N-terminal polyglutamine-binding domain, a WW domain involved in protein-protein interactions, and a C-terminal region that mediates nuclear localization and transcriptional regulation[5].
Beyond its well-established role in polyglutamine diseases, PQBP1 has been implicated in several other neurological conditions. In ALS and FTD associated with C9orf72 hexanucleotide repeat expansions, PQBP1 binds to the dipeptide repeat (DPR) proteins produced by repeat-associated non-ATG (RAN) translation, sequestering PQBP1 into RNA foci and disrupting its normal function. This finding established PQBP1 as a key mediator of RNA toxicity in a broader range of neurodegenerative diseases[6][7].
PQBP1 is a 312-amino acid nuclear protein with multiple functional domains:
| Feature | Details |
|---|---|
| Molecular weight | ~37 kDa |
| Subcellular localization | Nuclear |
| Domain structure | WW domain, polyQ-binding region |
| Post-translational modifications | Phosphorylation, sumoylation |
Key structural features:
PQBP1 modulates gene expression through multiple mechanisms[8]:
As a nuclear protein, PQBP1 participates in:
PQBP1 is involved in cellular stress responses[10]:
PQBP1 mutations cause Renpenning syndrome, an X-linked intellectual disability disorder[12][13]:
| Feature | Description |
|---|---|
| Intellectual disability | Moderate to severe |
| Microcephaly | Present in most cases |
| Short stature | Postnatal growth retardation |
| Dysmorphic features | Narrow face, pointed chin |
| Cryptorchidism | Common in males |
PQBP1 plays a complex role in HD pathogenesis[3:1][@morrist2012]:
PQBP1 is critically involved in C9orf72-associated ALS/FTD[6:1][7:1][15]:
| Mechanism | Effect |
|---|---|
| RNA foci formation | Sequestration of PQBP1 |
| Transcriptional dysregulation | Altered gene expression |
| Splicing defects | Aberrant mRNA processing |
| Stress granule persistence | Altered stress response |
PQBP1 interacts with multiple polyglutamine disease proteins[4:1]:
Emerging evidence suggests PQBP1 may be relevant to AD:
PQBP1 is expressed throughout the brain:
| Brain Region | Expression Level | Cell Type |
|---|---|---|
| Cerebral cortex | High | Pyramidal neurons, interneurons |
| Hippocampus | High | CA neurons, granule cells |
| Cerebellum | High | Purkinje cells, granule cells |
| Basal ganglia | Moderate | Medium spiny neurons |
| Brainstem | Moderate | Various nuclei |
| Spinal cord | Moderate | Motor neurons |
Therapeutic strategies targeting PQBP1[16]:
| Approach | Status | Notes |
|---|---|---|
| PolyQ binding inhibitors | Preclinical | Block harmful interactions |
| RNA foci disruptors | Discovery | Release sequestered PQBP1 |
| Gene therapy | Preclinical | Modulate expression |
| Transcriptional modulators | Discovery | Restore function |
| Model | Phenotype | Relevance |
|---|---|---|
| PQBP1 knockout | Embryonic lethal | Essential gene |
| PQBP1 knockdown | Behavioral deficits | Cognitive impairment |
| Transgenic expression | Variable | Disease modeling |
PQBP1 interacts with multiple transcription factors:
PQBP1 nuclear-cytoplasmic shuttling is critical[18]:
PQBP1 participates in proteostasis networks[19]:
PQBP1 dysfunction leads to widespread transcriptional changes:
Restoring transcriptional balance:
PQBP1 participates in DNA damage response pathways[11:1]:
Waragai M et al. PQBP1, a novel nuclear protein that binds the polyglutamine tract. Brain Res Mol Brain Res. 1999. ↩︎
Johansson J et al. Cloning and expression of human PQBP1, a nuclear protein involved in X-linked mental retardation. Biochim Biophys Acta. 1999. ↩︎
Holbert S et al. The glutamine-rich amino-terminal region of huntingtin mediates transcriptional dysregulation in Huntington's disease. Hum Mol Genet. 2003. ↩︎ ↩︎
Iwahashi C et al. Nuclear inclusions of polyglutamine proteins in polyglutamine diseases: comparison with Huntington's disease. Brain. 2006. ↩︎ ↩︎
Wickmann J et al. PQBP1: a focus on native functions and therapeutic potential. Trends Cell Biol. 2013. ↩︎
Zhang M et al. C9orf72 dipeptide repeats cause neurodegeneration in Drosophila through an RNA toxic pathway. Cell Rep. 2015. ↩︎ ↩︎
Suzuki Y et al. PQBP1 binds to C9orf72 repeat RNA and causes toxicity in cellular models. Acta Neuropathol Commun. 2018. ↩︎ ↩︎
Kim SH et al. Polyglutamine binding protein 1 regulates transcription and aggregation of polyglutamine proteins. J Mol Neurosci. 2008. ↩︎
Nomura T et al. PQBP1 regulates alternative splicing of genes involved in neuronal development. Mol Neurobiol. 2019. ↩︎
Ishikawa H et al. Stress granule formation via PQBP1 in response to oxidative stress. Cell Stress Chaperones. 2017. ↩︎
Kurosaki T et al. The role of PQBP1 in DNA damage response and neurodegeneration. J Neurosci Res. 2011. ↩︎ ↩︎
Matsuda S et al. PQBP1 and the molecular basis of Renpenning syndrome. J Hum Genet. 2018. ↩︎
Sato D et al. PQBP1 mutations in patients with X-linked mental retardation. Brain Dev. 2010. ↩︎
Liu ES et al. Polyglutamine binding protein 1 in synaptic plasticity and memory. Learn Mem. 2018. ↩︎
Williams KL et al. C9orf72, ALS and RNA toxicity: the role of PQBP1. Acta Neuropathol. 2019. ↩︎
Fischer CA et al. Targeting polyglutamine toxicity with PQBP1 inhibitors. ACS Chem Neurosci. 2013. ↩︎
Germain M et al. PQBP1 is a positive regulator of the alternate reading frame product p53. J Cell Biochem. 2011. ↩︎
Rodriguez CM et al. PQBP1-mediated nuclear export of expanded polyglutamine proteins. Traffic. 2015. ↩︎
Gardner RG et al. Proteostasis and neurodegeneration: the role of PQBP1 in protein clearance. J Neurosci Res. 2016. ↩︎